Saturday, September 23, 2006
Article in today's Los Angeles Times -- Drug Safety Overhaul Is Urged, by Ricardo Alonso-Zaldivar and Denise Gellene:
The government's drug safety system is seriously out of balance, devoting too much
attention to approving new medications and not enough follow-up to uncovering risky
side effects, a blue-ribbon scientific panel concluded in a major report released Friday.
Convened at the request of the Food and Drug Administration after a popular painkiller
was linked to heart attacks, the experts in medicine, pharmacology, law and other fields
issued a sweeping call for reform. Its 25 recommendations include establishing a fixed
term for the FDA commissioner, restricting ubiquitous drug commercials and placing a
special cautionary symbol on the packaging of newly approved medications.